𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti–tumor necrosis factor agents infliximab and etanercept

✍ Scribed by J. Braun; X. Baraliakos; J. Listing; J. Sieper

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
56 KB
Volume
52
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

To estimate the incidence of anterior uveitis in patients with ankylosing spondylitis (AS) who underwent anti–tumor necrosis factor (anti‐TNF) therapy, using data from recently performed trials.

Methods

Data from 4 placebo‐controlled studies with anti‐TNF agents in AS (2 with etanercept and 2 with infliximab) and 3 open‐label studies were analyzed for the prestudy prevalence and the incidence of reported flares of anterior uveitis.

Results

A total of 717 patients who received treatment for anterior uveitis during the course of published clinical studies were identified by a systematic literature search using Medline. Followup information on the course of anterior uveitis was available for 397 patients. Of these, 297 were exposed to etanercept and 90 were exposed to infliximab for a total of 430 and 146.4 years, respectively. Among 190 patients who received placebo, the overall exposure was 70.5 years. The frequency of flares of anterior uveitis in the placebo group was 15.6 per 100 patient‐years (95% confidence interval 7.8–27.9), while the patients treated with anti‐TNF agents had a mean of only 6.8 anterior uveitis flares per 100 patient‐years (P = 0.01). Flares of anterior uveitis occurred less frequently (although not significantly) in patients treated with infliximab than in patients treated with etanercept (3.4 per 100 patient‐years and 7.9 per 100 patient‐years, respectively).

Conclusion

Treatment of AS patients with biologic agents directed against TNFα is associated with a significant decrease in the number of anterior uveitis flares. This reduction was slightly more marked among patients treated with infliximab, but the difference was not significant.

📜 SIMILAR VOLUMES

Differences in the incidence of flares o
Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents
✍ Braun, J. ;Baraliakos, X. ;Listing, J. ;Davis, J. ;van der Heijde, D. ;Haibel, H 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Abstract ## Objective Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are clinically and pathologically linked. Anti–tumor necrosis factor (anti‐TNF) agents are efficacious in treating AS, but not all are equally effective in treating IBD (Crohn's disease [CD] and ulcerative co

Individualized monitoring of drug bioava
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
✍ Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C. Kapetan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 1 views

## Abstract ## Objective Infliximab, an anti–tumor necrosis factor α (anti‐TNFα) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be b